San Francisco startup Structure Therapeutics is likewise focusing on an oral, when-everyday GLP-one drug known as GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June every time a mid-stage study confirmed typical weight loss of all-around six% and it plans to start out a